Literature DB >> 21576922

Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.

Ariane Groth1, Stephan Klöss, Elke Pogge von Strandmann, Ulrike Koehl, Joachim Koch.   

Abstract

Human natural killer (NK) cells recognize and efficiently eliminate MHC class I low or negative malignant targets and virally infected host cells, without requirement for prior sensitization. However, viruses and various tumor cells display elaborate adaptations to evade and overcome immunosurveillance. The current review focuses on escape mechanisms of viruses and malignantly transformed 'stressed' cells to evade from NK cell cytotoxicity. A general overview of recent clinical studies using allogeneic donor NK cells is given, summarizing first data about a possible benefit for patients suffering from high-risk leukemia and solid tumors. Finally, the review discusses the future perspectives and hypotheses aiming to improve therapeutic NK cell strategies against tumor immune escape mechanisms.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21576922     DOI: 10.1159/000327014

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  27 in total

1.  Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Authors:  Julia Herrmann; Hannah Berberich; Jessica Hartmann; Steffen Beyer; Karen Davies; Joachim Koch
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

2.  The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.

Authors:  Jessica Hartmann; Thuy-Van Tran; Janina Kaudeer; Karin Oberle; Julia Herrmann; Isabell Quagliano; Tobias Abel; André Cohnen; Volker Gatterdam; Andrea Jacobs; Bernd Wollscheid; Robert Tampé; Carsten Watzl; Andreas Diefenbach; Joachim Koch
Journal:  J Biol Chem       Date:  2012-07-17       Impact factor: 5.157

Review 3.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 4.  Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.

Authors:  Peniel M Dimberu; Ralf M Leonhardt
Journal:  Yale J Biol Med       Date:  2011-12

5.  Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.

Authors:  Guillaume Onyeaghala; Heather H Nelson; Bharat Thyagarajan; Amy M Linabery; Angela Panoskaltsis-Mortari; Myron Gross; Kristin E Anderson; Anna E Prizment
Journal:  Mol Carcinog       Date:  2017-05-24       Impact factor: 4.784

Review 6.  Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Authors:  Joachim Koch; Michael Tesar
Journal:  Transfus Med Hemother       Date:  2017-09-11       Impact factor: 3.747

Review 7.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 8.  BAG-6, a jack of all trades in health and disease.

Authors:  Janina Binici; Joachim Koch
Journal:  Cell Mol Life Sci       Date:  2013-12-04       Impact factor: 9.261

9.  Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.

Authors:  Angeline S Andrew; Jiang Gui; Ting Hu; Asaf Wyszynski; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Sam A Tanyos; Eben M Pendleton; Rebecca M Ekstrom; Zhongze Li; Michael S Zens; Mark Borsuk; Jason H Moore; Margaret R Karagas
Journal:  BJU Int       Date:  2014-03-26       Impact factor: 5.588

Review 10.  Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Authors:  Michelle L Saetersmoen; Quirin Hammer; Bahram Valamehr; Dan S Kaufman; Karl-Johan Malmberg
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.